Pipeline
How far each program has come.
Anixa advances multiple programs in parallel across two modalities, each developed with a leading research or clinical institution.
DiscoveryPreclinicalPhase 1Phase 2/3
Lira-celCAR-T · Ovarian cancer
DiscoveryPreclinicalPhase 1Phase 2/3
Phase 1 · dose escalationWith
Moffitt Cancer Center
The Wistar Institute
Moffitt Cancer CenterThe Wistar InstituteBreast cancer vaccineVaccine · Breast cancer
DiscoveryPreclinicalPhase 1Phase 2/3
Phase 1 · preparing Phase 2With
Cleveland Clinic
Department of Defense
Cleveland ClinicDepartment of DefenseStatus reflects most recent public disclosure.How the technologies work
Reading the pipeline.
- Lira-cel (ovarian cancer CAR-T). Phase 1, dose escalation underway, with positive survival observations reported. Developed with Moffitt Cancer Center and The Wistar Institute.
- Breast cancer vaccine. Phase 1 complete and preparing for a neo-adjuvant Phase 2. Developed with Cleveland Clinic and the U.S. Department of Defense.
Follow the programs as they progress.
Get press releases and trial updates through investor relations, or reach out directly.